Research and Development Services Agreement - Bio-Technology General Corp. and Bio-Technology General (Israel) Ltd.
AMENDED AND RESTATED RESEARCH AND
DEVELOPMENT SERVICES AGREEMENT
THIS AGREEMENT, made and entered into as of this 28th day of December,
1995, by and between BIO-TECHNOLOGY GENERAL CORP., a Delaware corporation ('BTG
U.S.'), and BIO-TECHNOLOGY GENERAL (ISRAEL) LTD., an Israeli corporation ('BTG
W I T N E S S E T H :
WHEREAS, BTG ISRAEL has experience in the research and development of
genetically engineered and other products and has the facilities, equipment and
employees that will permit it to carry out research and development activities
on behalf of BTG U.S.; and
WHEREAS, pursuant to a Research and Development Agreement dated as of May
9, 1983, BTG U.S. has engaged BTG ISRAEL to render research and development
services to BTG U.S. in connection with BTG U.S.' research and development
activities, and BTG ISRAEL is willing to provide such services; and
WHEREAS, from time to time BTG U.S. and BTG ISRAEL have modified the terms
under which BTG ISRAEL provides research and development services to BTG U.S.;
WHEREAS, BTG U.S. and BTG ISRAEL desire to amend and restate the terms
under which BTG ISRAEL will continue to provide research and development
services to BTG U.S.
NOW, THEREFORE, in consideration of the foregoing and for other good and
valuable consideration, the receipt and sufficiency of which are hereby
acknowledged, the parties hereto hereby agree as follows:
1. Definitions. The following terms used in this Agreement shall have the
meanings set forth below:
1.1. 'Affiliate' shall mean an entity or person that directly, or
indirectly through one or more intermediaries, controls, is controlled by, or is
under common control with, BTG U.S. For this purpose 'control' means the direct
or indirect beneficial ownership of fifty percent (50%) or more of an entity's
voting stock or equity.
1.2. 'Chief Scientist' shall mean the office of the Chief Scientist of the
State of Israel or any successor entity.
1.3. 'Principal Investigators' shall mean those scientists and technicians
at Research Institutions who engage or participate in the conduct or supervision
of a Sponsored Research Program.
1.4. 'Product' shall mean each and every product which embodies or is
manufactured by the use of, or which contains components which embody or are
produced by, the Technology.
1.5. 'Reimbursable Costs' shall mean all direct and indirect costs
(including without limitation an allocable share of BTG ISRAEL's administrative
expenses) incurred by BTG ISRAEL in conducting the Sponsored Research Program or
in providing technical assistance pursuant to Section 4 hereof, all as
determined in accordance with United States generally accepted accounting
principles. Such costs shall include, without limitation, salaries and wages,
payroll taxes, contract labor, fringe benefits, facilities (including leasehold
improvements) and equipment repair and maintenance expenses, recruitment and
relocation expenses, communication expense, supplies, development and prototype
materials, freight and transportation, training, education, travel expenses,
data processing costs, license fees, insurance, professional or other outside
purchased services (including, without limitation, services performed by the
Principal Investigators), depreciation and amortization of, and financing
charges for, capital acquisitions made on or after January 1, 1994, sales and
use taxes, and periodic lease payments under capital or financing leases of
assets acquired by BTG ISRAEL or any Research Institution for use in conducting
the Sponsored Research Program. Such costs shall not include any exchange losses
incurred as a result of any fluctuation in the rate of exchange between the
Israel Shekel and the U.S. dollar. BTG ISRAEL shall document the allocation of
indirect costs, which allocations shall be submitted to BTG U.S. for its review
and approval, which approval shall not be unreasonably withheld. Such allocation
of indirect costs shall be reviewed by the parties in December of each year to
determine whether such allocation should be revised for the next fiscal year.
Notwithstanding the foregoing, Reimbursable Costs shall not include the direct
and indirect costs of the Sponsored Research Program which are funded by the
Chief Scientist unless and until BTG ISRAEL is obligated to reimburse the Chief
Scientist for such funding, in which event Reimbursable Costs shall include the
amounts due the Chief Scientist in respect of such Sponsored Research Program,
up to 100% of the amount of the Sponsored Research Program funded by the Chief
Scientist (denominated in U.S. Dollars). All third party costs shall be charged
to BTG U.S. in an amount equal to the payments made by BTG ISRAEL to any such
third party in respect of the research and development.
1.6. 'Research Institutions' shall mean those universities, research
institutions and other organizations which, pursuant to written agreements with
BTG ISRAEL, will undertake to conduct, supervise or participate in a Sponsored
1.7. 'Sponsored Research Program' shall mean a research and development
program which is conducted by BTG ISRAEL or by one or more Research
Institution(s) under an agreement with BTG ISRAEL pursuant to the terms and
conditions of this Agreement.
1.8. 'Technology' shall mean all information and know-how (general and
specific) including, without limitation, developments, discoveries, inventions,
improvements, designs, methods, processes, techniques, devices, formulae and
trade secrets which hereafter are developed, acquired, conceived, result from or
arise in connection with a Sponsored Research Program.
2. Research and Development Services.
2.1. From time to time during the term of this Agreement, BTG ISRAEL agrees
to undertake, at BTG U.S.'s request, Sponsored Research Programs in accordance
with the terms of this Agreement. Each such Sponsored Research Program shall be
initiated by the submission by BTG U.S. to BTG ISRAEL of a written proposed
project plan which shall include:
(i) the estimated budget for the first year of the Sponsored Research
(ii) a proposed development plan setting forth the activities to be
carried out, the objectives sought to be achieved, and the projected
duration of the Sponsored Research Program.
Any such Sponsored Research Program shall be considered effective and in full
force upon written concurrence thereto from an authorized representative of both
parties. BTG U.S. may make changes to and amend the Sponsored Research Program
and the project plan from time to time after consulting with BTG ISRAEL.
BTG ISRAEL hereby agrees to use its best efforts to accomplish the research
contemplated by such Sponsored Research Program, directly and/or by arrangement
with Research Institutions, including without limitation expending sufficient
time and effort and allocating sufficient staff, but does not guarantee or
warrant the results of the Sponsored Research Program.
2.2. At least ninety (90) days prior to the end of the first year of any
Sponsored Research Program (or any subsequent year if any Sponsored Research
Program is extended), BTG ISRAEL and BTG U.S. shall commence good faith
discussions of the budget and any revisions in the project plan with the intent
of establishing a one-year budget therefor no later than sixty (60) days prior
to the end of the current year.
2.3. During the term of this Agreement, BTG ISRAEL shall devote such time
and effort to the performance of services pursuant to this Agreement as may be
necessary or appropriate to fulfill its duties as described in Section 2;
however, it is specifically understood and agreed by BTG U.S. that BTG ISRAEL
shall not be required to devote full time to such services and that BTG ISRAEL
shall have the right to engage in its own research and development activities,
which may include research and development activities which may be competitive
with the Sponsored Research
Programs and in other business activities with other persons, and BTG U.S. shall
not, by virtue of this Agreement, have any right, title or interest in or to
such independent activities or to the income or profits derived therefrom and,
without limiting BTG ISRAEL's obligation to use commercially reasonable efforts
to provide certain services hereunder, nothing set forth in this Agreement shall
limit or reduce the ability of BTG ISRAEL to carry on such other activities.
2.4. BTG ISRAEL shall maintain its research and development
facilities, and shall conduct its research and development services, in
accordance with Good Laboratory Practices as required from time to time.
3. Payment for Services.
3.1. As compensation for the services to be performed by BTG ISRAEL
hereunder on behalf of BTG U.S., BTG U.S. agrees to pay to BTG ISRAEL its
Reimbursable Costs incurred in each Sponsored Research Program, all as set forth
in this Section 3.
3.2. At the beginning of each fiscal quarter, BTG U.S. shall advance to BTG
ISRAEL one quarter of the total budget for each Sponsored Research Program for
the fiscal year or such other amount as indicated in the budget for the
particular quarter. Within thirty (30) days after the end of each quarter, BTG
ISRAEL shall furnish to BTG U.S. a written report of its Reimbursable Costs for
each Sponsored Research Program for that quarter. If the Reimbursable Costs
exceed the advance, BTG U.S. shall promptly pay the difference to BTG ISRAEL; if
such Reimbursable Costs are less than the advance, such difference shall be
credited in U.S. dollars toward the advance for the subsequent fiscal quarter.
All revenue received by BTG ISRAEL from pre-commercial sales of products in
accordance with Section 5 hereof shall be treated as an advance to BTG ISRAEL
pursuant to this Section 3 and shall be credited in U.S. Dollars toward the
advance for the subsequent fiscal quarter due BTG ISRAEL pursuant to this
BTG ISRAEL shall keep full and true books of account and other records in
sufficient detail so that the Reimbursable Costs payable to BTG ISRAEL hereunder
can be properly ascertained. BTG ISRAEL agrees, at the request of and expense of
BTG U.S., to permit an independent certified public accountant selected by BTG
U.S. (except one to whom BTG ISRAEL has some reasonable objection) to have
access, once each calendar year, during ordinary business hours, to such books
and records as may be necessary to determine in respect to invoices for
Reimbursable Costs delivered not more than two (2) years prior to the date of
such request the correctness of any determination of the Reimbursable Costs
contained in such invoice, but in no event shall any invoice be reviewed more
than once. The basis for any determination of such accountant shall be made
available for review and comment by BTG ISRAEL and reconsidered if BTG ISRAEL so
requests, and a further determination made at BTG ISRAEL's expense by another
nationally recognized independent certified public accountant selected by BTG
U.S. from among three proposed by BTG ISRAEL and such
accountant shall make a final determination. Such final determination shall be
binding upon the parties hereto.
3.3. BTG ISRAEL shall use its reasonable best efforts to obtain funding on
an annual basis for a portion of each Sponsored Research Program from the Chief
3.4. BTG U.S. shall bear all risks of loss attributable to the research and
development activities performed on its behalf by BTG ISRAEL. BTG ISRAEL shall
be entitled to retain the entire amount of Reimbursable Costs received pursuant
to this Section, whether or not the research and development work is successful
and accomplished the results contemplated by any Sponsored Research Program.
4. Technical Assistance. BTG ISRAEL agrees to make available to BTG U.S. or
its designee, at reasonable times and places and on reasonable notice, the
services of technical personnel to consult with, instruct and assist BTG U.S. or
its designee in utilizing the Technology.
5. Pre-Commercial Sales. BTG ISRAEL shall, at the request of BTG U.S., sell
products to third parties who have obtained license or distribution rights in
respect of such products for use by such third parties in conducting clinical
tests and obtaining regulatory approval to market such products. All amounts
received by BTG ISRAEL in respect of such sales shall, for purposes of this
Agreement, be treated as advances of payments due BTG ISRAEL hereunder.
6. Reports and Records.
6.1. BTG ISRAEL shall furnish BTG U.S. within sixty (60) days of the end of
each of BTG ISRAEL's fiscal quarters a report in such reasonable detail as BTG
U.S. may request setting forth:
(a) the work performed by BTG ISRAEL during such quarter with respect
to such Sponsored Research Program; and
(b) the status of such Sponsored Research Program at the end of such
In addition, BTG ISRAEL shall furnish to BTG U.S. such information regarding the
status of the sponsored Research Program as BTG U.S. may from time to time
6.2. Within ninety (90) days after the completion of such Sponsored
Research Program, BTG ISRAEL shall provide to BTG U.S. a final report in such
reasonable detail as BTG U.S. may request setting forth all Reimbursable Costs
incurred by BTG ISRAEL in connection therewith.
6.3. BTG ISRAEL shall keep complete, accurate and authentic accounts,
notes, data and records relating to such Sponsored Research Program in the
manner and form approved by BTG U.S. Such accounts, notes, data and records
shall be available for inspection and copying by BTG U.S. and its authorized
representative during regular business hours.
6.4. BTG ISRAEL shall provide to BTG U.S. such data and information
resulting from its conduct of the Sponsored Research Program and such reasonable
assistance as BTG U.S. may reasonably require in connection with preparing
applications required for governmental approval of, and obtaining approval of,
the use, marketing and distribution of the product(s) resulting from the
Sponsored Research Program.
7. Ownership and Patents.
7.1. BTG U.S. shall have exclusive right, title and interest in and to the
Technology, and BTG ISRAEL shall have no rights with respect thereto. The
parties hereto recognize and agree that BTG ISRAEL is merely rendering research
and development services to BTG U.S., and that BTG U.S. is the developer of the
Nothing herein is intended to derogate from BTG ISRAEL's ownership of the
real property, tools, machinery and equipment acquired by it in furtherance of,
or incidental to, any Sponsored Research Program, whether or not the research
and development work is successful and accomplishes the results contemplated by
any such Sponsored Research Program.
7.2. Any patent applications or patents for the Technology shall be owned
by BTG U.S., and BTG ISRAEL shall have no rights with respect thereto. BTG U.S.
shall have sole control over filing and prosecuting applications for United
States and foreign patents covering the Technology and shall file and prosecute
the same in BTG U.S.'s name. The cost for all such filings and prosecutions
shall be borne by BTG U.S. BTG ISRAEL agrees to use its best efforts to cause
each of its employees and consultants and each Research Institution (and each
Principal Investigator thereat) working on a Sponsored Research Program to enter
into a binding written agreement, reasonably acceptable to BTG U.S., to the
effect that (i) if such person is a sole inventor or joint inventor of
Technology, such employee, consultant or Principal Investigator will, without
further compensation, provide BTG U.S. with the necessary authorizations, powers
of attorney and other documents and assistance reasonably requested by BTG U.S.
to secure and maintain BTG U.S.'s patent rights in the United States and/or
foreign countries and (ii) such person shall safeguard the secrecy and
confidentiality of, and the proprietary rights of BTG U.S. in and to, the
Technology and any information relating thereto, and to use the Technology and
any information relating thereto solely in connection with such Sponsored
Research Program. BTG ISRAEL will use its reasonable efforts to cause such
Research Institution(s) and Principal Investigator(s) to fulfill their
obligations under such agreements.
Notwithstanding anything herein to the contrary, the parties acknowledge
that under certain agreements previously entered into by BTG ISRAEL with
Research Institutions, patent rights with respect to certain Technology are, and
will continue to be, owned by such Research Institutions.
7.3. Within sixty (60) days of (i) delivering a certificate signed by an
officer of BTG ISRAEL certifying completion of a Sponsored Research Program or
(ii) termination of such Sponsored Research Program pursuant to Section 9
hereof, BTG ISRAEL will transfer and deliver to BTG U.S. all property and
property rights in which BTG U.S. has ownership rights pursuant to Section 7.1
above held by or under the control of BTG ISRAEL relating to such Sponsored
8. Disclosure of Information.
8.1. BTG ISRAEL shall not furnish copies of documents, patents, patent
applications, copyrights, drawings, specifications, bills of materials, devices,
equipment, prototypes and other information relating to the Technology other
than as contemplated by this Agreement and shall not, without prior written
approval of BTG U.S., disclose such information to any third party except to the
extent that such disclosure is necessary to BTG ISRAEL's performance of a
Sponsored Research Program, and then only if (i) such disclosure is subject to
the same limitations on the recipient as on BTG ISRAEL, and (ii) such
limitations are set forth in a written agreement in form and substance
satisfactory to BTG U.S.
8.2. Unless previously so delivered, within sixty (60) days after the
termination of this Agreement for any reason, BTG ISRAEL shall deliver to BTG
U.S. all information and all other property in which BTG U.S. has ownership
rights pursuant to Section 7 of this Agreement.
8.3. No publication with respect to any activity undertaken pursuant to any
Sponsored Research Program shall be made, nor any manuscript submitted for
publication, without the prior review and written approval of BTG U.S.
8.4. The parties hereto agree that remedies at law may be inadequate to
protect against the breach of this Section 8, and in any case of such a breach
BTG ISRAEL hereby consents to the granting of injunctive relief, whether
temporary, preliminary or final, in favor of BTG U.S. without proof of actual
8.5. The provisions of this Section 8 shall survive the termination of this
Agreement notwithstanding the reason for such termination.
9. Term and Termination.
9.1. This Agreement shall commence as of the date first written above, and
shall continue in full force and effect unless terminated pursuant to this
9.2. This Agreement shall terminate upon:
(a) the mutual consent of the parties hereto; or
(b) a party sending notice to the other party of termination of this
Agreement upon the occurrence of any of the following events:
(i) the other party institutes bankruptcy, insolvency,
liquidation or receivership proceedings or proceedings for
reorganization under bankruptcy or comparable laws;
(ii) a petition is filed against the other party for any such
proceedings listed in (i) above, the effectiveness of which is not
stayed or dismissed within ninety (90) days after the filing thereof;
(iii) the other party shall make a general assignment for the
benefit of creditors; or
(iv) the other party shall commit any material breach of any of
the terms or conditions hereof, and also shall fail to remedy such
default or breach within ninety (90) days after receipt of written
notice thereof from the other party.
9.3. Notwithstanding the termination of this Agreement as provided in this
Section 9, the rights and obligations of the parties under Sections 7 and 8
hereof shall survive such termination and remain in full force and effect.
10. Research Institutions and Principal Investigators. BTG ISRAEL may enter
into agreements with Research Institutions whereby such institutions and/or the
Principal Investigators undertake to perform all or any portion of a Sponsored
Research Program; provided, however, that (except with prior written approval of
BTG U.S.) no such agreement shall contain any provision which restricts the
rights conferred upon BTG U.S. hereunder or diminishes the obligations of BTG
ISRAEL hereunder which would be required to be performed by BTG ISRAEL if no
such agreement had been made. Nothing in this Section 10 is intended to derogate
from the provisions of Section 7.2.
11. Relationship of the Parties. Nothing in this Agreement or in the
performance hereof shall have the effect of making BTG U.S. and BTG ISRAEL
partners, joint venturers or each other's agents, and neither shall have the
right to act on behalf of or bind the other except as expressly provided
hereunder or otherwise expressly agreed in writing, and each party shall
indemnify and hold harmless the other against and from any liability arising
from any such act by such party. BTG ISRAEL
will render the research and development services provided for herein as an
12. Headings. All section headings used in this Agreement are solely for
the convenience of the parties and shall not affect the meaning or
interpretation of the provisions thereof.
13. Governing Law; Consent to Jurisdiction. This Agreement shall be
governed by and construed in accordance with the laws of the State of New York
(not including its choice of law principles). The parties hereto submit to the
exclusive jurisdiction and venue of the Supreme Court of the State of New York
and the Federal District Court for the Southern District of New York for
purposes of any legal action arising out of this Agreement.
14. Entire Agreement. This Agreement constitutes the entire agreement
between the parties with respect to the subject matter hereof and supersedes and
replaces all prior agreements, understandings, writings and discussions between
the parties, including without limitation that certain Research and Development
Services Agreement, dated as of May 9, 1983.
15. Amendment; Nonwaiver. This Agreement, and any of the terms hereof,
shall not be modified, amended or waived except by a written instrument executed
by the parties or, in the case of a waiver, by the waiving party. The failure of
either party at any time to require performance of any term hereof shall not
affect its right at a later time to enforce such term. The waiver by either
party of any condition or term hereof in any one or more instances shall not be
construed as a further or continuing waiver of such condition or term.
16. Unenforceable Provision. If any provision of this Agreement is, or
becomes or is deemed to be invalid, illegal or unenforceable in any respect in
any jurisdiction, such provision shall be deemed amended to conform to
applicable laws so as to be valid and enforceable or, if it cannot be so amended
without materially altering the intention of the parties, it shall be stricken
and the remainder of this Agreement shall remain in full force and effect.
In case any one or more of the provisions contained in this Agreement shall
be held invalid, illegal or unenforceable in any respect in any jurisdiction,
the validity, legality and enforceability of such provision or provisions shall
not in any way be affected or impaired thereby in any other jurisdiction; and
the validity, legality and enforceability of the remaining provisions contained
herein shall not in any way be otherwise affected or impaired thereby.
17. Notices. All notices and other communications required or desired to be
given or sent by one party to the other party shall be in writing, in the
English language, and shall be deemed to have been given (a) on the date of
delivery, if delivered to the persons identified below, (b) five calendar days
after mailing if mailed,
with proper postage, by certified or registered airmail, postage prepaid, return
receipt requested, addressed as set forth below, (c) on the date of receipt if
sent by telex or telecopy, and confirmed in writing in the manner set forth in
(b) on or before the next day after the sending of the telex or telecopy, or (d)
two business days after delivered to an internationally recognized overnight
courier service marked for overnight delivery, as follows:
To BTG U.S.: Bio-Technology General Corp.
70 Wood Avenue South
Iselin, New Jersey 08830
To BTG ISRAEL: Bio-Technology General (Israel) Ltd.
Rehovot 76326, Israel
Any party may change such party's address for notices by notice duly given
pursuant to this Section 17.
18. Assignment. Neither this Agreement nor any right or obligation arising
hereunder may be assigned by BTG ISRAEL in whole or in part, without the prior
written consent of BTG U.S., which consent may be withheld in the absolute
discretion of BTG U.S. BTG U.S. may, upon written notice to BTG ISRAEL, assign
this Agreement or any part hereof without the prior consent of BTG ISRAEL,
subject to any limitation imposed by any agreement (approved by BTG U.S.) to
which BTG ISRAEL is a party. This Agreement shall be binding upon any assignee
and, subject to the restrictions on assignment herein set forth, inure to the
benefit of the successors and assigns of each of the parties hereto.
19. Counterparts. This Agreement may be executed in one or more
counterparts, each of which shall be deemed an original; but such counterparts
shall together constitute but one and the same instrument.
IN WITNESS WHEREOF, the parties have executed this Agreement as of the date
first set forth above.
BIO-TECHNOLOGY GENERAL CORP.
BIO-TECHNOLOGY GENERAL (ISRAEL) LTD.